Hydrocortisone Therapy with CAR Peptide Protects the Injured Endothelial Glycocalyx in Sepsis.

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10973
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Emergency medicine
• Research Institution: Gifu University
• Principal Investigator: YOSHIDA Takahiro 岐阜大学, 大学院医学系研究科, 助教 (40452148)
• Co-Investigator(Kenkyū-buntansha): 岡田 英志 岐阜大学, 医学部附属病院, 講師 (30402176) ; 竹村 元三 朝日大学, 歯学部, 教授 (40283311) ; 鈴木 浩大 岐阜大学, 医学部附属病院, 助教 (80724583)
• Research Collaborator: SUGAHARA Kazuki
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 敗血症

Outline of Final Research Achievements

A tissue-penetrating homing peptide, CARSKNKDC (CAR) has previously demonstrated the unique ability to facilitate transport of co-administered drugs into injured endothelial cell. Co-administration of hydrocortisone and CAR could improve the endothelial disorder and survival in sepsis using lower amounts of hydrocortisone.Mice were given lipopolysaccharide (LPS, 20 mg/kg). Subsequently, five different treatments were initiated: saline only; CAR peptide-alone administration 500 ug; hydrocortisone 0.2mg/kg or 10mg/kg ; and CAR co-administered with hydrocortisone 0.2mg/kg. Hydrocortisone and /or CAR peptide were injected intraperitoneally at 3, 12 and 24 hours after LPS administration. Forty-eight hours after LPS administration, combined thrapy group showed the best survival ratio. These results suggest that co-administration of hydrocortisone and CAR peptide is a highly effective treatment strategy for endothelial disorder in sepsis.

Free Research Field

集中治療医学